Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2

Lehrer et al., In Vivo, 34:5, 3023-3026, doi:10.21873/invivo.12134
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19ivm.org
In silico analysis showing ivermectin may interfere with the attachment of the spike to the human cell membrane.
68 preclinical studies support the efficacy of ivermectin for COVID-19:
Ivermectin, better known for antiparasitic activity, is a broad spectrum antiviral with activity against many viruses including H7N766, Dengue32,67,68, HIV-168, Simian virus 4069, Zika32,70,71, West Nile71, Yellow Fever72,73, Japanese encephalitis72, Chikungunya73, Semliki Forest virus73, Human papillomavirus52, Epstein-Barr52, BK Polyomavirus74, and Sindbis virus73.
Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins66,68,69,75, shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing33, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination36,76, shows dose-dependent inhibition of wildtype and omicron variants31, exhibits dose-dependent inhibition of lung injury56,61, may inhibit SARS-CoV-2 via IMPase inhibition32, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation5, inhibits SARS-CoV-2 3CLpro49, may inhibit SARS-CoV-2 RdRp activity24, may minimize viral myocarditis by inhibiting NF-κB/p65-mediated inflammation in macrophages55, may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation77, shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-1954,78, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage4, may minimize SARS-CoV-2 induced cardiac damage35,43, increases Bifidobacteria which play a key role in the immune system79, has immunomodulatory46 and anti-inflammatory65,80 properties, and has an extensive and very positive safety profile81.
Lehrer et al., 19 Jun 2020, peer-reviewed, 2 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperIvermectinAll
Common drugs, vitamins, nutritional supplements and COVID-19 mortality
Dr Steven Lehrer, Peter H Rheinstein
doi:10.3892/ijfn.2021.14
The FDA has approved only one drug, remdesivir, for the treatment of COVID-19. The FDA has granted an emergency use authorization for the rheumatoid arthritis treatment drug, baricitinib (Olumiant), for the treatment of COVID-19 in some cases. For this reason, investigators have paid considerable attention to the association between commonly used drugs and the outcome of patients with COVID-19. Aspirin and ibuprofen have been reported to reduce the mortality rate. Omeprazole can increase mortality. In addition, some studies have demonstrated that famotidine diminishes mortality, while others have indicated that famotidine leads to a poorer prognosis. The present study used UK Biobank (UKB) data to assess the association of commonly used drugs with COVID-19 mortality. Data processing was performed on Minerva, a Linux mainframe with Centos 7.6. The UK Biobank Data Parser (ukbb_parser) was used, a python-based package that allows easy interfacing with the large UK Biobank dataset. The results revealed that aspirin and omeprazole were associated with an elevated mortality rate. Ibuprofen-related mortality was lower than laxative-related mortality. Aspirin users were also significantly older than other subjects. The association with mortality of cholesterol-lowering medications, blood pressure-lowering medications, hormone replacement and oral contraceptives in 134 female subjects revealed insignificant variability. The association of nutritional supplements in 238 subjects with mortality indicated that variability was insignificant. The lower mortality linked to the supplementation of vitamin D and vitamin B, presumably B complex, has been previously observed. On the whole, the present study demonstrates that although some of the associations described among drugs and This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.
Ethics approval and consent to participate All patient data were from the UK Biobank. The UK Biobank application for the present study was approved as UKB project 57245, SL and PHR. Patient consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Author Manuscript The research reported in the present study was supported by the Office of Research Infrastructure of the National Institutes of Health under award nos. S10OD018522 and S10OD026880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Author Manuscript
References
Aly, Ma, Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy?, Med Hypotheses
Atkins, Masoli, Delgado, Pilling, Kuo et al., Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort, J Gerontol A Biol Sci Med Sci
Cangiano, Fatti, Danesi, Gazzano, Croci et al., Mortality in an Italian nursing home during COVID-19 pandemic: Correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests, Aging
Chow, Khanna, Kethireddy, Yamane, Levine et al., Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19, Anesth Analg, doi:10.1213/ANE.0000000000005292
Flora, Maestra, Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19, FASEB J
Haque, Jawed, Akhter, Dar, Khan et al., Acetylsalicylic acid (Aspirin): A potent medicine for preventing COVID-19 deaths caused by thrombosis and pulmonary embolism, Eur Rev Med Pharmacol Sci
Kelleni, Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes, Biomed Pharmacother
Khanji, Aung, Chahal, Petersen, COVID-19 and the UK Biobank-Opportunities and challenges for research and collaboration with other large population studies, Front Cardiovasc Med
Kim, Read, Fauci, Therapy for early COVID-19: A critical need, JAMA
Kutti Sridharan, Kotagiri, Chandiramani, Mohan, Vegunta et al., COVID-19 and avoiding Ibuprofen. How good is the evidence?, Am J Ther
Lee, Ha, Yeniova, Moon, Kim et al., Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching, Gut
Mather, Seip, Mckay, Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19, Am J Gastroenterol
Murai, Fernandes, Sales, Pinto, Goessler et al., Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2020.26848
Pavoni, Gianesello, Pazzi, Stera, Meconi et al., Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action, Thromb Res
Rinott, Kozer, Shapira, Haim, Ibuprofen use and clinical outcomes in COVID-19 patients, Clin Microbiol Infect
Rubin, Sorting out whether vitamin D deficiency raises COVID-19 risk, JAMA
Tan, Ho, Kalimuddin, Cherng, Teh et al., Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19), Nutrition
Umhau, Casting sunlight on an epidemic: Is vitamin D a critical host factor to prevent COVID-19?, J Infect Dis
Yuan, Wang, Chan, Zhang, Cheng et al., Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virusassociated pneumonia in Syrian hamsters, Nat Microbiol
Zhou, Wang, Lee, Wu, Cheung et al., Proton pump inhibitor or famotidine use and severe COVID-19 disease: A propensity score-matched territory-wide study, Gut
Zhu, Salminen, Thompson, Jahanshad, The UK Biobank Data Parser: A tool with built in and customizable filters for brain studies
{ 'indexed': {'date-parts': [[2024, 5, 11]], 'date-time': '2024-05-11T15:12:52Z', 'timestamp': 1715440372631}, 'reference-count': 0, 'publisher': 'Anticancer Research USA Inc.', 'issue': '5', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020]]}, 'DOI': '10.21873/invivo.12134', 'type': 'journal-article', 'created': {'date-parts': [[2020, 8, 31]], 'date-time': '2020-08-31T23:25:21Z', 'timestamp': 1598916321000}, 'page': '3023-3026', 'source': 'Crossref', 'is-referenced-by-count': 96, 'title': 'Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2', 'prefix': '10.21873', 'volume': '34', 'author': [ {'given': 'STEVEN', 'family': 'LEHRER', 'sequence': 'first', 'affiliation': []}, {'given': 'PETER H.', 'family': 'RHEINSTEIN', 'sequence': 'additional', 'affiliation': []}], 'member': '9336', 'published-online': {'date-parts': [[2020, 8, 31]]}, 'container-title': 'In Vivo', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.21873/invivo.12134', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 4, 30]], 'date-time': '2022-04-30T12:32:03Z', 'timestamp': 1651321923000}, 'score': 1, 'resource': {'primary': {'URL': 'http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.12134'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020]]}, 'references-count': 0, 'journal-issue': { 'issue': '5', 'published-online': {'date-parts': [[2020, 8, 31]]}, 'published-print': {'date-parts': [[2020]]}}, 'alternative-id': ['10.21873/invivo.12134'], 'URL': 'http://dx.doi.org/10.21873/invivo.12134', 'relation': {}, 'ISSN': ['0258-851X', '1791-7549'], 'subject': [], 'container-title-short': 'In Vivo', 'published': {'date-parts': [[2020]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit